CN113260366B - 3β- (苄氧基) -17α-甲基-孕甾-5-烯-20-酮用于治疗认知障碍 - Google Patents
3β- (苄氧基) -17α-甲基-孕甾-5-烯-20-酮用于治疗认知障碍 Download PDFInfo
- Publication number
- CN113260366B CN113260366B CN201980081303.1A CN201980081303A CN113260366B CN 113260366 B CN113260366 B CN 113260366B CN 201980081303 A CN201980081303 A CN 201980081303A CN 113260366 B CN113260366 B CN 113260366B
- Authority
- CN
- China
- Prior art keywords
- 3bn17mep
- cognitive
- mice
- disorders
- rimonabant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4 | 2018-12-18 | ||
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113260366A CN113260366A (zh) | 2021-08-13 |
| CN113260366B true CN113260366B (zh) | 2024-03-08 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980081303.1A Active CN113260366B (zh) | 2018-12-18 | 2019-12-18 | 3β- (苄氧基) -17α-甲基-孕甾-5-烯-20-酮用于治疗认知障碍 |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101506172A (zh) * | 2006-07-14 | 2009-08-12 | 辉瑞产品公司 | (7S)-7-[(5-氟-2-甲基-苄基)氧基]-2-[(2R)-2-甲基哌嗪-1-基]-6,7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐 |
| CN105189529A (zh) * | 2012-11-28 | 2015-12-23 | 国家医疗保健研究所 | 孕烯醇酮的3-(4’-取代的)-苄基-醚衍生物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234125A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| CN101790521A (zh) | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CN106983754A (zh) | 2011-05-20 | 2017-07-28 | 国家医疗保健研究所 | Cb1受体拮抗剂 |
| LT2976074T (lt) * | 2013-03-19 | 2020-03-25 | Universitat Pompeu-Fabra | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
| IL276697B2 (en) | 2018-02-20 | 2024-08-01 | Aelis Farma | 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101506172A (zh) * | 2006-07-14 | 2009-08-12 | 辉瑞产品公司 | (7S)-7-[(5-氟-2-甲基-苄基)氧基]-2-[(2R)-2-甲基哌嗪-1-基]-6,7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐 |
| CN105189529A (zh) * | 2012-11-28 | 2015-12-23 | 国家医疗保健研究所 | 孕烯醇酮的3-(4’-取代的)-苄基-醚衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pratt et al. | Amyotrophic lateral sclerosis: update and new developments | |
| Bernard-Marissal et al. | Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration | |
| CN109310692B (zh) | 治疗眼部病状的方法 | |
| KR20170048426A (ko) | 시각 장애를 치료하기 위한 조성물 및 방법 | |
| JP2009102343A (ja) | ダウン症候群を有する成人において認知低下を阻害する方法 | |
| WO2011147889A1 (en) | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient | |
| KR102845328B1 (ko) | 인지 장애의 치료시 사용하기 위한 3β-(벤질옥시)-17α-메틸-프레근-5-엔-20-온 | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| US20200345746A1 (en) | Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents | |
| US20190015395A1 (en) | Tacrolimus for treating tdp-43 proteinopathy | |
| RU2796005C2 (ru) | 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| KR20250121149A (ko) | 소아 헌팅턴병 치료를 위한 프리도피딘 | |
| HK40060558A (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| HK40060558B (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| CN117813095A (zh) | 用于治疗肌萎缩侧索硬化症的vcp抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |